A B S T R A C T Two siblings with mild hemorrhagic symptoms had combined functional deficiencies of vitamin K-dependent clotting factors. Prothrombin (0.18-0.20 U/ml) and Stuart factor (Factor X, 0.18-0.20 U/ml) were most severely affected. Antigenic amounts of affected coagulation factors were normal and normal generation of thrombin activity occurred in the patients' plasmas after treatment with nonophysiologic activators that do not require calcium for prothrombin activation. Hepatobilary disease, malabsorptive disorders, and plasma warfarin were not present. Both parents had normal levels of all coagulation factors. The patients' plasmas contained prothrombin that reacted both with antibody directed against des-y-carboxyprothrombin and native prothrombin. Crossed immunoelectrophoresis of patients' plasmas and studies of partially purified patient prothrombin suggested the presence of a relatively homogeneous species of dysfunctional prothrombin, distinct from the heterologous species found in the plasma of warfarin-treated persons. These studies are most consistent with a posttranslational defect in hepatic carboxylation of vitamin K-dependent factors. This kindred uniquely possesses an autosomal recessive disorder of vitamin K-dependent factor formation that causes production of an apparently homogeneous species of dysfunctional prothrombin; the functional deficiencies in clotting factors are totally corrected by oral or parenteral administration of vitamin KI.
appear to serve as binding sites for calcium ligands that attach to phospholipid and to proteolytic activators of the clotting factors (6) (7) (8) (9) . Vitamin K is necessary for the carboxylation reaction, which is coupled to oxidative conversion of vitamin K to a 2,3-epoxide derivative. Vitamin K epoxide is then sequentially reduced to regenerate the form necessary to support the linked carboxylation-oxidation reactions (10, 11) . Administration of coumarinlike drugs impairs formation of Gla residues on the vitamin K-dependent factors, apparently by inhibition of the enzyme(s) responsible for reduction of the vitamin K epoxide metabolite (10) .
Heritable deficiencies of individual vitamin K-dependent factors other than Factor IX are rare. The pattern of inheritance appears to be autosomal recessive, and the deficient coagulation factor activity may reflect either a true deficiency state or the presence of dysfunctional zymogen (12) . In one family, deficiency of Factor X was sometimes associated with a deficiency in Factor VII (13) . In other cases, a functional deficiency of prothrombin was associated with deficiencies of Factors VII or X (14, 15) , and in one kindred deficient Factor VII and Factor IX activities were independently inherited (16) .
Two previously reported cases of congenital, combined deficiencies of vitamin K-dependent factors have had characteristics indicative of defective Gla residue formation and/or function (17) (18) (19) ). An additional patient with deficiencies of all four vitamin 1 Abbreviations used in this paper: BCS, barbital-citratesaline buffer; Gla, y-carboxyglutamic acid; RVV, Russell's viper venom; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis. K-dependent factors was less extensively characterized (20) .
This report describes a kindred possessing an abnormality of vitamin K-dependent coagulation factors. The abnormality present in affected members of this family has clinical and biochemical features distinct from those of the two cases previously described.
METHODS

Case reports
The index patient (A.B.), a 20-yr-old woman in 1980, has a lifelong history of easy bruising, epistaxis, spontaneous gingival bleeding, and prolonged bleeding after dental extractions. She required transfusion for anemia resulting from pubertal menorrhagia at age 13. Between ages 18 and 20, she was hospitalized three times for severe vaginal hemorrhage despite hormonal regulation of menses. One of these episodes was complicated by intraperitoneal hemorrhage documented at laporatomy and was followed by repeated hemorrhage at the operative site. She also suffers intermittently from a polyarticular, nondeforming, seronegative arthritis.
Her brother (M.F., 18 yr old) had no history of abnormal bleeding except for hemorrhage requiring transfusion after dental extraction at age seven. He is otherwise well and has no symptoms of arthritis.
Between Rabbit antisera against human prothrombin and human Factor X were purchased from Calbiochem-Behring Corp., and were the gift of Dr. E. W. Davie, Seattle, respectively.
Antiserum against prothrombin, after heat inactivation or isolation of a crude IgG fraction (26) selectively neutralized the prothrombin activity of normal pooled plasma without neutralizing other vitamin K-dependent clotting factors after incubation with an equal part of normal plasma for 2 h at 370C. This antiserum formed a single band upon double immunodiffusion against normal, Factor X-deficient, Factor IX-deficient or Factor VII-deficient plasmas. After absorption with an equal volume of human Factor X-deficient plasma, a crude IgG fraction of antiserum against Factor X showed similar selective neutralization of Factor X activity in normal plasma.
Adsorption of vitamin K-dependent factors from normal and abnormal plasmas was performed for some assays by mixing with 1/10 vol C-y-alumina for 10 min at room temperature followed by centrifugation at 30,000 g for 30 min at 2°C. For use in coagulation factor antigen assays and for purification of clotting factors, 1/10 vol 1 M BaCl2 was added to plasma, then mixed and centrifuged in the same fashion. Supernatant solutions from the latter adsorption procedure were dialyzed against the appropriate buffer before assay.
Blood coagulation factors were assayed in one-stage tests (22, 27) . Assays of the prothrombin time, (PT), activated partial thromboplastin time (aPTT), fibrinogen concentration, and platelet function were performed by previously described techniques (28) . Prothrombin assay with staphylocoagulase (29) was performed in 10 X 75-mm glass tubes by incubating 0.1 ml substrate (human oxalated serum-bovine absorbed plasma (27) ) with 0.1 ml test plasma, diluted in BCS buffer, for 1 min at 37°C, then adding 0.1 ml prewarmed staphylocoagulase (5 mg/ml in the same buffer), and tilting until a visible clot was observed. Percent normal activity was obtained from a curve of clotting times observed with serial dilutions of normal pooled plasma in BCS buffer; this curve corresponded to that obtained from plasma composed of appropriate ratios of normal pooled plasma and alumina gel-adsorbed normal plasma. Assay of prothrombin by venom from Echis carinatus (18) was performed in the same way, using 0.1 ml prewarmed E. carinatus venom (10 mg/ml BCS buffer). Activation of prothrombin by venom of Oxyuranus Scutellatus sctUtellatus (Taipan viper venom) (30) was performed in a similar fashion, except that test plasma dilutions were in barbital-saline buffer, and 0.2 ml of an equal mixture of Taipan viper venom, 0.1 mg/ml, and 0.025 M CaC12 was added before assay. Assay for activation of Factor X by RVV (31) , was performed in the presence of calcium by preincubating 0.1 ml substrate (Factor X-deficient) plasma, for 1 min at 370C with 0.1 ml test or normal pooled plasma, serially diluted in barbital-saline buffer, and then adding, in order, 0.1 ml RVV (0.1 mg/ml) and 0.1 ml Centrolex-CaC12 mixture.
Antigenic material reacting with heterologous antibody to either human prothrombin or human Factor X were assayed both by radial immunodiffusion and, more quantitatively, by antibody neutralization using the same heterologous antibody. For the latter assay, equal volumes of diluted heat-inactivated antiserum and varying dilutions of test or control plasma were incubated for 2 h at 37°C, additionally incubated at 58°C for 60 min, and then centrifuged at 2,000 g for 20 min. The supernatant solutions were then incubated at 370C with diluted pooled normal plasma for 60 min and assayed for residual prothrombin activity. The percent prothrombin antigen was estimated from a log-log curve of the clotting times obtained after incubation of the antibody with serial dilutions of normal pooled plasma. This curve corresponded to a curve obtained with equivalent dilutions of normal pooled plasma in alumina-adsorbed normal plasma; duplicate test samples varied from each other by .10 % over a range of prothrombin antigen equivalent to 12.5-100% the amount present in normal pooled plasma.
Radial immunodiffusfon and double immunodiffusion were carried out in 1% agarose in barbital-saline buffer, pH 7.4 (22) . Crossed immunoelectrophoresis was performed with 1 % agarose in 0.075 M sodium barbital (pH 8.6) containing 2 mM calcium lactate at room temperature (18, 32 Measurements of (a) abnormal (des-y-carboxy) prothrombin, (b) normal prothrombin, and (c) total prothrombin in patient and normal plasmas were performed using immunoassays described elsewhere (33).2 In brief, the antibodies used were directed at (a) a prothrombin species deficient in Gla residues (des-y-carboxy-prothrombin), (b) a fully carboxylated prothrombin species (normal prothrombin), and (c) the carboxy-terminal antigenic determinants common to both abnormal prothrombin and prothrombin (total prothrombin) (33 
RESULTS
The index patient and her brother had significant prolongation of both the PT and aPTT (Table I) ; these abnormalities were corrected by the addition of an equal volume of normal plasma. Individual factor assays showed significant deficiency of Stuart factor (Factor X) and prothrombin and variable, mild deficiency in Christmas factor (Factor IX). Factor VII levels were normal. Assays for fibrin stabilizing factor (Factor XIII) and platelet aggregation in response to ADP, collagen, and ristocetin were normal. The patient's mother and father had normal levels of all vitamin K-dependent factors (Table I) .
The titer of immunoreactive prothrombin, as measured by an antibody reactive only with prothrombin among the vitamin K-dependent coagulation factors, exceeded the prothrombin titer obtained in coagulation assays (Table II) (Fig. 1) . This result was obtained in seven different electrophoreses using varying conditions of buffer, ionic strength, voltage, and duration of electrophoresis. The anodal "shoulder" seen with the normal plasma sample was a constant finding with both pooled and single donor normal plasmas electrophoresed under the conditions described. To supplement visual inspection of .0 FIGURE 1 Crossed immunoelectrophoresis. Top, normal plasma; Middle, A.B. plasma; Bottom, plasma from patient on warfarin therapy. The first dimension was run for 6.5 h at 20 V/cm, and the second dimension for 17 h at 20 V/cm. Both dimensions were run in 1% agarose in 0.075 M sodium barbital containing 2 mM calcium lactate, pH 8.6 . The second dimension contained specific antiprothrombin antibody.
prothrombin mobility in normal and abnormal plasmas, the observed mobility in the first dimension was compared with the mobility, relative to normal plasma, expected by the ratio: albumin migration (normal plasma)/albumin migration (abnormal plasma) = prothrombin migration (normal)/prothrombin migration (abnormal).
Under the electrophoresis conditions used, the prothrombin mobility in patient plasma was 6-7 mm anodal to that predicted for normal prothrombin by this formula. Prothrombin from patients receiving warfarin separated into two apparent populations migrating 0-2 mm and 9-11 mm anodal to the mobility of normal prothrombin. The height and staining intensity of the more anodal peak was roughly proportional to the degree of prolongation of the prothrombin time. The warfarin-treatment plasma illustrated ( As noted previously (18, 19) , the presence of calcium in electrophoresis buffer was required for demonstration of differential electrophoretic mobility.
The patients' plasma also contained an increased amount of prothrombin reactive with antibody specific for human prothrombin deficient in Gla residues (33) ( Table III) . In addition, a significant reduction was observed in the patients' plasma of prothrombin immunoreactive in a radioimmunoassay specific for prothrombin containing a full complement of Gla residues. Their father's plasma also contained a small, but significant amount of Gla-deficient prothrombin antigen. Appreciable abnormal prothrombin remained in patient A.B.'s plasma after treatment with vitamin K1 had resulted in normal prothrombin activity. The assay of abnormal prothrombin uses antiabnormal prothrombin antibodies that likely vary in their affinity for different abnormal prothrombin species (33). Accordingly, the measured level of abnormal prothrombin must be considered a lower limit of the amount of abnormal prothrombin present in A.B.'s plasma.
Partial purification of patient M.F.'s prothrombin was achieved by BaCl2 adsorption, elution with EDTA, and anion-exchange chromatography identical to that used for isolation of normal human prothrombin (34) Abnormal prothrombin, quantitated with anti-abnormal prothrombin specific antibody, includes acarboxy-and descarboxyforms of prothrombin.
§ Normal prothrombin, quantitated with antibodies specific for the calcium-stabilized prothrombin conformer, is the fully carboxylated prothrombin species. I Total prothrombin, quantitated using antiprethrombin I antibodies, is specific for the COOH-terminal domain, and includes all prothrombin species. ( Fig. 2) . Pooled fractions of both normal and the patient's prothrombin showed a single band of -80,000 mol wt on SDS-PAGE both in the presence and absence of f3-mercaptoethanol. While the prothrombin antigen content of the two preparations corresponded well, the ratio of activity to antigen showed the same discrepancy found in studies of whole plasma (Table II) . DISCUSSION The presence of multiple abnormalities of vitamin Kdependent coagulation factors in siblings, coupled with the history of correction of the prothrombin time of the propositus by parenteral vitamin Kl, suggested the presence of an abnormality in vitamin-K dependent posttranslational modification of these proteins. Determination of the ratios of activity to antigen for the affected coagulation factors and the demonstration of normal thrombin generation in the patients' plasmas after treatment with nonphysiologic activators that do not require the presence of calcium for prothrombin activation offered additional support for the hypothesis that the plasmas in this kindred contained a prothrombin species similar to that which results from vitamin K deficiency states or treatment with vitamin K antagonists (8, 10, 11) . Specific radioimmunoassay for normal and des-a-carboxy prothrombin also indicated the presence in the patients' plasmas of prothrombin deficient in Gla residues.
The long history of a bleeding disorder in the proband, the detection of a prolonged prothrombin time when no medications were being taken, the presence of the same abnormality in her sibling, and the absence of detectable warfarin in their plasmas appears to rule out the presence of an exogenous inhibitor of normal prothrombin synthesis. Careful evaluation excluded malabsorptive or maldigestive disorders. These studies, then, suggest that the affected siblings had either a selective defect in vitamin K absorption or a hepatic abnormality in vitamin K metabolism. Since the titer of Factor VII was normal, and that of Factor IX only marginally decreased, a selective defect in the absorption of vitamin K from the gut or impaired transport of vitamin K into the hepatocyte seems unlikely. Impaired utilization of the vitamin within these cells better explains the data obtained.
Crossed immunoelectrophoresis in a calcium-containing buffer suggested the presence in the patients' plasma of prothrombin molecules exhibiting a larger net negative charge than normal prothrombin when saturated with calcium ions. The crossed-immunoelectrophoretic pattern of this prothrombin was distinct from that seen with the heterogeneous prothrombin species found in plasma of patients treated with warfarin. The patients' single symmetrical peak also differed from the patterns obtained in studies of similar cases (18, 19) . Consistent with these results, patient M.F.'s prothrombin, partially purified from plasma by techniques identical to those used for partial purification of normal prothrombin, retained the excess of antigenic material to procoagulant activity found in studies of whole plasma.
This kindred appears to have an abnormality of vitamin K-dependent coagulation factors distinct from those previously described, both clinically and biochemically. The patient reported by McMillan et al. (17) and subsequently further evaluated by Chung et al. (18) , had a severe (<1% activity) deficiency of all evaluated vitamin K-dependent factors; the patient reported by Johnson et al. (19) had mild combined deficiencies of vitamin-K dependent factors analogous to the levels found in our family of patients. Both of these patients had prothrombin with sufficiently variable electrophoretic mobility to produce two peaks on crossed immunoelectrophoresis. Also in contrast to our kindred, only partial (18) and no (19) correction of coagulation factor deficiencies occurred after treatment with vitamin KI.
Our data are most consistent with a defect in the posttranslational vitamin K-dependent formation of Gla residues that resulted in a relatively homogeneous population of dysfunctional prothrombin, as compared with the heterogeneously carboxylated prothrombins that characterize the plasma of patients receiving prolonged oral anticoagulant therapy. Pending direct analysis of the other affected coagulation factors, it seems likely that this hereditary defect is responsible for an identical abnormality of posttranslational carboxylation. Normal functional levels of the involved factors in both parents with equally affected siblings, of both sexes, suggests an autosomal recessive inheritance pattern of expression for this defect.
